WallStreetZenWallStreetZen

NASDAQ: RLYB
Rallybio Corp Stock Forecast, Predictions & Price Target

Analyst price target for RLYB

Based on 4 analysts offering 12 month price targets for Rallybio Corp.
Min Forecast
$6.00+430.97%
Avg Forecast
$10.00+784.96%
Max Forecast
$15.00+1,227.43%

Should I buy or sell RLYB stock?

Based on 4 analysts offering ratings for Rallybio Corp.
Buy
Strong Buy
0 analysts 0%
Buy
4 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RLYB stock forecasts and price targets.

RLYB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-10-01
lockedlocked$00.00+00.00%2024-08-26
lockedlocked$00.00+00.00%2024-04-19
lockedlocked$00.00+00.00%2024-04-11

1 of 1

Forecast return on equity

Is RLYB forecast to generate an efficient return?
Company
N/A
Industry
-748.45%
Market
49.39%

Forecast return on assets

Is RLYB forecast to generate an efficient return on assets?
Company
N/A
Industry
26.75%

RLYB earnings per share forecast

What is RLYB's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.45
Avg 2 year Forecast
-$1.17
Avg 3 year Forecast
-$0.58

RLYB revenue forecast

What is RLYB's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$300.0k+0.33%
Avg 2 year Forecast
$8.3M+2,679.26%
Avg 3 year Forecast
$67.5M+22,478.6%
RLYB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RLYB revenue growth forecast

How is RLYB forecast to perform vs Biotechnology companies and vs the US market?
Company
479.55%
Industry
35.42%
Market
9.66%
RLYB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RLYB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RLYB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RLYB$1.13$10.00+784.96%Buy
VOR$0.69$10.70+1,450.72%Buy
AADI$1.94$1.75-9.79%Hold
AFMD$3.16$17.50+453.80%Strong Buy
HOOK$4.02$39.25+876.37%Buy

Rallybio Stock Forecast FAQ

Is Rallybio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: RLYB) stock is to Buy RLYB stock.

Out of 4 analysts, 0 (0%) are recommending RLYB as a Strong Buy, 4 (100%) are recommending RLYB as a Buy, 0 (0%) are recommending RLYB as a Hold, 0 (0%) are recommending RLYB as a Sell, and 0 (0%) are recommending RLYB as a Strong Sell.

If you're new to stock investing, here's how to buy Rallybio stock.

What is RLYB's earnings growth forecast for 2024-2026?

(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.77%.

Rallybio's earnings in 2024 is -$73,881,000.On average, 3 Wall Street analysts forecast RLYB's earnings for 2024 to be -$60,020,091, with the lowest RLYB earnings forecast at -$64,720,634, and the highest RLYB earnings forecast at -$57,667,745. On average, 3 Wall Street analysts forecast RLYB's earnings for 2025 to be -$48,403,567, with the lowest RLYB earnings forecast at -$64,720,634, and the highest RLYB earnings forecast at -$34,019,821.

In 2026, RLYB is forecast to generate -$24,062,800 in earnings, with the lowest earnings forecast at -$24,062,800 and the highest earnings forecast at -$24,062,800.

What is RLYB's revenue growth forecast for 2024-2028?

(NASDAQ: RLYB) Rallybio's forecast annual revenue growth rate of 479.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.66%.

Rallybio's revenue in 2024 is $299,000.On average, 2 Wall Street analysts forecast RLYB's revenue for 2024 to be $12,446,276, with the lowest RLYB revenue forecast at $12,446,276, and the highest RLYB revenue forecast at $12,446,276. On average, 1 Wall Street analysts forecast RLYB's revenue for 2027 to be $344,761,840, with the lowest RLYB revenue forecast at $344,761,840, and the highest RLYB revenue forecast at $344,761,840.

In 2028, RLYB is forecast to generate $2,800,826,931 in revenue, with the lowest revenue forecast at $2,800,826,931 and the highest revenue forecast at $2,800,826,931.

What is RLYB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RLYB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 26.75%.

What is RLYB's Price Target?

According to 4 Wall Street analysts that have issued a 1 year RLYB price target, the average RLYB price target is $10.00, with the highest RLYB stock price forecast at $15.00 and the lowest RLYB stock price forecast at $6.00.

On average, Wall Street analysts predict that Rallybio's share price could reach $10.00 by Oct 1, 2025. The average Rallybio stock price prediction forecasts a potential upside of 784.96% from the current RLYB share price of $1.13.

What is RLYB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: RLYB) Rallybio's current Earnings Per Share (EPS) is -$1.78. On average, analysts forecast that RLYB's EPS will be -$1.45 for 2024, with the lowest EPS forecast at -$1.56, and the highest EPS forecast at -$1.39. On average, analysts forecast that RLYB's EPS will be -$1.17 for 2025, with the lowest EPS forecast at -$1.56, and the highest EPS forecast at -$0.82. In 2026, RLYB's EPS is forecast to hit -$0.58 (min: -$0.58, max: -$0.58).

What is RLYB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RLYB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.